Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis

Molecular and cellular mechanistic insights

Misato Hashizume, Seng Lai Tan, Junichi Takano, Kazunori Ohsawa, Ikuo Hasada, Akira Hanasaki, Ichiro Ito, Masahiko Mihara, Keiichiro Nishida

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Pro-inflammatory cytokines play a major role in the initiation and maintenance of joint inflammation and destruction in rheumatoid arthritis (RA). The therapeutic success of biologics targeting tumour necrosis factor-alpha (TNF-α), interleukin-1 (IL-1) and interleukin (IL)-6 receptor (IL-6R) has broadened the treatment options for RA. These agents have potential overlapping and discriminating biologic effects, as well as different pharmacological features. Tocilizumab (TCZ) is a humanized monoclonal antibody that binds and neutralizes IL-6R, resulting in the inhibition of various IL-6-mediated biological activities, including inflammation-related, immunomodulatory and tissue/matrix remodelling effects. Randomized, double-blind, controlled phase III studies and a number of early clinical observational studies have shown that treatment with TCZ results in rapid and sustained improvement in the signs and symptoms of RA among different patient populations. These studies have established the efficacy and safety of TCZ. Here, we review the pleiotropic functions of IL-6 and how it impinges on many aspects of RA pathogenesis, and highlight the clinical experience to date with TCZ as an emerging new treatment option for RA.

Original languageEnglish
Pages (from-to)265-279
Number of pages15
JournalInternational Reviews of Immunology
Volume34
Issue number3
DOIs
Publication statusPublished - May 4 2015

Fingerprint

Interleukins
Rheumatoid Arthritis
Antibodies
Interleukin-6
Inflammation
Therapeutics
Interleukin-6 Receptors
Antibodies, Monoclonal, Humanized
Biological Products
Interleukin-1
Signs and Symptoms
Observational Studies
Tumor Necrosis Factor-alpha
Joints
Maintenance
tocilizumab
Pharmacology
Cytokines
Safety
Population

Keywords

  • Actermra
  • Anemia
  • Atherosclerosis
  • Inflammation
  • Interleukin-6
  • Rheumatoid arthritis
  • Tocilizumab
  • Tumor necrosis factor-alpha

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis : Molecular and cellular mechanistic insights. / Hashizume, Misato; Tan, Seng Lai; Takano, Junichi; Ohsawa, Kazunori; Hasada, Ikuo; Hanasaki, Akira; Ito, Ichiro; Mihara, Masahiko; Nishida, Keiichiro.

In: International Reviews of Immunology, Vol. 34, No. 3, 04.05.2015, p. 265-279.

Research output: Contribution to journalArticle

Hashizume, Misato ; Tan, Seng Lai ; Takano, Junichi ; Ohsawa, Kazunori ; Hasada, Ikuo ; Hanasaki, Akira ; Ito, Ichiro ; Mihara, Masahiko ; Nishida, Keiichiro. / Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis : Molecular and cellular mechanistic insights. In: International Reviews of Immunology. 2015 ; Vol. 34, No. 3. pp. 265-279.
@article{07a080b644194d01a7959687e627e1f7,
title = "Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: Molecular and cellular mechanistic insights",
abstract = "Pro-inflammatory cytokines play a major role in the initiation and maintenance of joint inflammation and destruction in rheumatoid arthritis (RA). The therapeutic success of biologics targeting tumour necrosis factor-alpha (TNF-α), interleukin-1 (IL-1) and interleukin (IL)-6 receptor (IL-6R) has broadened the treatment options for RA. These agents have potential overlapping and discriminating biologic effects, as well as different pharmacological features. Tocilizumab (TCZ) is a humanized monoclonal antibody that binds and neutralizes IL-6R, resulting in the inhibition of various IL-6-mediated biological activities, including inflammation-related, immunomodulatory and tissue/matrix remodelling effects. Randomized, double-blind, controlled phase III studies and a number of early clinical observational studies have shown that treatment with TCZ results in rapid and sustained improvement in the signs and symptoms of RA among different patient populations. These studies have established the efficacy and safety of TCZ. Here, we review the pleiotropic functions of IL-6 and how it impinges on many aspects of RA pathogenesis, and highlight the clinical experience to date with TCZ as an emerging new treatment option for RA.",
keywords = "Actermra, Anemia, Atherosclerosis, Inflammation, Interleukin-6, Rheumatoid arthritis, Tocilizumab, Tumor necrosis factor-alpha",
author = "Misato Hashizume and Tan, {Seng Lai} and Junichi Takano and Kazunori Ohsawa and Ikuo Hasada and Akira Hanasaki and Ichiro Ito and Masahiko Mihara and Keiichiro Nishida",
year = "2015",
month = "5",
day = "4",
doi = "10.3109/08830185.2014.938325",
language = "English",
volume = "34",
pages = "265--279",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis

T2 - Molecular and cellular mechanistic insights

AU - Hashizume, Misato

AU - Tan, Seng Lai

AU - Takano, Junichi

AU - Ohsawa, Kazunori

AU - Hasada, Ikuo

AU - Hanasaki, Akira

AU - Ito, Ichiro

AU - Mihara, Masahiko

AU - Nishida, Keiichiro

PY - 2015/5/4

Y1 - 2015/5/4

N2 - Pro-inflammatory cytokines play a major role in the initiation and maintenance of joint inflammation and destruction in rheumatoid arthritis (RA). The therapeutic success of biologics targeting tumour necrosis factor-alpha (TNF-α), interleukin-1 (IL-1) and interleukin (IL)-6 receptor (IL-6R) has broadened the treatment options for RA. These agents have potential overlapping and discriminating biologic effects, as well as different pharmacological features. Tocilizumab (TCZ) is a humanized monoclonal antibody that binds and neutralizes IL-6R, resulting in the inhibition of various IL-6-mediated biological activities, including inflammation-related, immunomodulatory and tissue/matrix remodelling effects. Randomized, double-blind, controlled phase III studies and a number of early clinical observational studies have shown that treatment with TCZ results in rapid and sustained improvement in the signs and symptoms of RA among different patient populations. These studies have established the efficacy and safety of TCZ. Here, we review the pleiotropic functions of IL-6 and how it impinges on many aspects of RA pathogenesis, and highlight the clinical experience to date with TCZ as an emerging new treatment option for RA.

AB - Pro-inflammatory cytokines play a major role in the initiation and maintenance of joint inflammation and destruction in rheumatoid arthritis (RA). The therapeutic success of biologics targeting tumour necrosis factor-alpha (TNF-α), interleukin-1 (IL-1) and interleukin (IL)-6 receptor (IL-6R) has broadened the treatment options for RA. These agents have potential overlapping and discriminating biologic effects, as well as different pharmacological features. Tocilizumab (TCZ) is a humanized monoclonal antibody that binds and neutralizes IL-6R, resulting in the inhibition of various IL-6-mediated biological activities, including inflammation-related, immunomodulatory and tissue/matrix remodelling effects. Randomized, double-blind, controlled phase III studies and a number of early clinical observational studies have shown that treatment with TCZ results in rapid and sustained improvement in the signs and symptoms of RA among different patient populations. These studies have established the efficacy and safety of TCZ. Here, we review the pleiotropic functions of IL-6 and how it impinges on many aspects of RA pathogenesis, and highlight the clinical experience to date with TCZ as an emerging new treatment option for RA.

KW - Actermra

KW - Anemia

KW - Atherosclerosis

KW - Inflammation

KW - Interleukin-6

KW - Rheumatoid arthritis

KW - Tocilizumab

KW - Tumor necrosis factor-alpha

UR - http://www.scopus.com/inward/record.url?scp=84928950382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928950382&partnerID=8YFLogxK

U2 - 10.3109/08830185.2014.938325

DO - 10.3109/08830185.2014.938325

M3 - Article

VL - 34

SP - 265

EP - 279

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 3

ER -